• September 27, 2016
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has been named one of Working Mother Magazine’s "100 Best Companies for Working Mothers" for the third consecutive year. The publication selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs such as flexibility, advancement, paid family leave and childcare. “Zoetis is honored to be among Working Mother Magazine’s topmore...
  • August 21, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that Glenn David, Senior Vice President of Finance Operations, has been named Executive Vice President and Chief Financial Officer (CFO), and will assume responsibility for the oversight of the company’s financial management, planning and global operations, effective immediately. As CFO, David will report directly to Chief Executive Officer Juan Ramón Alaix and become part of the Zoetis Executivemore...
  • August 11, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14, 2016, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.more...
  • August 8, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has completed the purchase of Scandinavian Micro Biodevices, a pioneer in developing and manufacturing microfluidic “lab on a chip” diagnostic analyzers and tests for veterinary point-of- care services for $80 million. The acquisition adds to Zoetis’ complementary point-of-care diagnostics portfolio, giving the company an expanded and promising pipeline in this fast-growing segment ofmore...
  • August 3, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2016 and increased its revenue and adjusted net income guidance for full year 2016. The company reported revenue of $1.2 billion for the second quarter of 2016, an increase of 3% compared with the second quarter of 2015. Net income for the second quarter of 2016 was $224 million, or $0.45 per diluted share, compared with a net loss of $37more...
  • June 30, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Wednesday, Aug. 3, 2016. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review second quarter financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://more...
  • May 31, 2016
    Zoetis scientists will present six abstracts at the 8th World Congress of Veterinary Dermatology (WCVD) that contribute to the body of evidence supporting the use of lokivetmab, an antibody designed specifically for dogs that inhibits the canine cytokine interleukin-31 (cIL-31). The data also advance scientific understanding of the role of IL-31 in canine atopic dermatitis. The WCVD takes place May 31 to June 4 in Bordeaux, France.Data Supporting the Efficacy of Lokivetmab in Canine Atopicmore...
  • May 18, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 36th Annual Growth Stock Conference on Tuesday, June 14, 2016, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. EDT (9:30 a.m. CDT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting httpmore...
  • May 16, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Dogs that experience fear and anxiety in response to loud noise such as fireworks, thunder, and construction work now have a new treatment option with the launch of SILEO® (dexmedetomidine oromucosal gel), the first and only medication approved by the U.S. Food and Drug Administration (FDA) for treatment of noise aversion in dogs. Noise aversion refers to the behavioral and clinical signs of fear and anxiety experienced by dogs in response tomore...
  • May 13, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Goldman Sachs 37th Annual Global Healthcare Conference on Tuesday, June 7, 2016, in Rancho Palos Verdes, Calif. Paul Herendeen, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:20 p.m. EDT (11:20 a.m. PDT). Investors and other interested parties will be able to access a livemore...